Najat Khan - 22 Dec 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Chief R&D Commercial Officer, Director
Issuer ticker: RXRX
Reported as of: 22 Dec 2025
Net transaction value: -$548,592
SEC form: 4
Accepted by SEC: 29 Dec 2025, 17:24:36 UTC
Prior SEC filing: 19 Nov 2025
Next SEC filing: 10 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kyle Nelson, attorney-in-fact

Key filing fact

Najat Khan filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 29 Dec 2025.

Key facts

This page summarizes Najat Khan's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 29 Dec 2025, 17:24.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: -$548,592.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002020969 Primary reporting owner

Khan Najat

Relationship: Chief R&D Commercial Officer, Director
Address: 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/ Kyle Nelson, attorney-in-fact
Signature date: 29 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Sale

Transaction value: $548,592
Shares: -124,403
Change %: -17%
Price: $4.41
Shares after: 611,135
Date: 22 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 169,851
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $4.96
Footnotes: F3

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 420,226
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $7.25
Footnotes: F4

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 993,944
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $7.34
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $4.30 to $4.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Footnote F4

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Footnote F5

This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.